Tags

Type your tag names separated by a space and hit enter

Androgen receptor polymorphisms and the incidence of prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1033-40.CE

Abstract

The human androgen receptor gene contains polymorphic CAG and GGC repeats in exon 1. We investigated whether the number of CAG and/or GGC repeats is related to prostate cancer risk in a case-control study nested within the beta Carotene and Retinol Efficacy Trial. Among 300 cases and 300 controls, we did not observe any increase in risk associated with fewer CAG or GGC repeats. We observed a nonsignificant decrease in risk associated with each unit of decrease in CAG length [odds ratio (OR), 0.98; 95% confidence interval (CI), 0.93-1.03). Men with CAG <22 had a relative risk of prostate cancer of 0.89 (95% CI, 0.65-1.23) compared with men with CAG > or =22. There was no appreciable difference in the mean number of GGC repeats between cases and controls; the estimated change in the risk of prostate cancer associated with one fewer GGC repeat was 0.97 (95% CI, 0.88-1.06). The risk in men at or below the mean number of GGC repeats (17) was 0.80 (95% CI, 0.57-1.12). In contrast to prior reports, men with both short CAG (<22) and short GGC (< or =17) repeats were not at increased risk of prostate cancer (OR, 0.56; 95% CI, 0.32-0.98), compared with men with > or =22 CAG repeats and >17 GGC repeats. Our results do not support the hypothesis that a small number of CAG or GGC repeats in the androgen receptor gene increases a man's risk of prostate cancer.

Authors+Show Affiliations

Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. cchen@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12376504

Citation

Chen, Chu, et al. "Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 10 Pt 1, 2002, pp. 1033-40.
Chen C, Lamharzi N, Weiss NS, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1033-40.
Chen, C., Lamharzi, N., Weiss, N. S., Etzioni, R., Dightman, D. A., Barnett, M., DiTommaso, D., & Goodman, G. (2002). Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(10 Pt 1), 1033-40.
Chen C, et al. Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1033-40. PubMed PMID: 12376504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Androgen receptor polymorphisms and the incidence of prostate cancer. AU - Chen,Chu, AU - Lamharzi,Najib, AU - Weiss,Noel S, AU - Etzioni,Ruth, AU - Dightman,Douglas A, AU - Barnett,Matt, AU - DiTommaso,Dante, AU - Goodman,Gary, PY - 2002/10/12/pubmed PY - 2002/12/27/medline PY - 2002/10/12/entrez SP - 1033 EP - 40 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 11 IS - 10 Pt 1 N2 - The human androgen receptor gene contains polymorphic CAG and GGC repeats in exon 1. We investigated whether the number of CAG and/or GGC repeats is related to prostate cancer risk in a case-control study nested within the beta Carotene and Retinol Efficacy Trial. Among 300 cases and 300 controls, we did not observe any increase in risk associated with fewer CAG or GGC repeats. We observed a nonsignificant decrease in risk associated with each unit of decrease in CAG length [odds ratio (OR), 0.98; 95% confidence interval (CI), 0.93-1.03). Men with CAG <22 had a relative risk of prostate cancer of 0.89 (95% CI, 0.65-1.23) compared with men with CAG > or =22. There was no appreciable difference in the mean number of GGC repeats between cases and controls; the estimated change in the risk of prostate cancer associated with one fewer GGC repeat was 0.97 (95% CI, 0.88-1.06). The risk in men at or below the mean number of GGC repeats (17) was 0.80 (95% CI, 0.57-1.12). In contrast to prior reports, men with both short CAG (<22) and short GGC (< or =17) repeats were not at increased risk of prostate cancer (OR, 0.56; 95% CI, 0.32-0.98), compared with men with > or =22 CAG repeats and >17 GGC repeats. Our results do not support the hypothesis that a small number of CAG or GGC repeats in the androgen receptor gene increases a man's risk of prostate cancer. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12376504/Androgen_receptor_polymorphisms_and_the_incidence_of_prostate_cancer_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=12376504 DB - PRIME DP - Unbound Medicine ER -